Pfizer-BioNTech COVID-19 vaccine, bivalent booster is authorized for use in people ages 6 months and older. Spahn stressed, however, that Germany's Health Ministry would await guidance from the Standing Committee on Vaccination at the national health agency, the Robert Koch Institute, before making a final decision.Now Administering First, Second and Bivalent Booster DosesĬhildren 6 months to 15 of age must be accompanied by a parent or guardian.Īvailable to eligible individuals age 6 months or older.Īvailable to those 6 months to 5 years of age and those age 18 or older.Īvailable to those age 12 and older who have not received any other COVID-19 vaccine. German Health Minister Jens Spahn confirmed this week that the government was considering extending the length of time between the first and second doses of the Pfizer-BioNTech vaccine, citing the example set by the U.K. It's a bid to provide as many people with some immunity as fast as possible to try and stem the dramatic spread of the virus, and it the U.K. With the worst COVID-19 epidemic in Europe, and one that is worsening fast, Britain's strategy was clearly born of urgency. People line up for a COVID-19 vaccination at Guys Hospital in London, England, on January 5, 2021. "If people do not truly know how protective a vaccine is, there is the potential for harm because they may assume that they are fully protected when they are not, and accordingly, alter their behavior to take unnecessary risks," the FDA warned. "Without appropriate data supporting such changes in vaccine administration, we run a significant risk of placing public health at risk, undermining the historic vaccination efforts to protect the population from COVID-19." "Suggesting changes to the FDA-authorized dosing or schedules of these vaccines is premature and not rooted solidly in the available evidence," the U.S. The FDA approved the Pfizer vaccine for emergency use with a maximum of 21 days between the first and second doses. The spokesperson said the Working Group "concluded that vaccine efficacy will be maintained with dosing intervals longer than 21 days… based on clinical trial data that showed the vaccine was 90.5% effective against preventing COVID-19 after the first dose once the protection that starts at around 12 days kicks in, and there was no evidence to suggest that the effectiveness of the vaccine is declining towards the end of the 21-day period following the first dose."īut as the FDA and Pfizer have said, there's also no data to show that the effectiveness of the first dose lasts until the 12-week mark, or anything near it.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |